SGMO Share Price Performance
US$0.42
-1.46 (-77.48%)
87.0% undervalued intrinsic discount
US$3.25
Fair Value
Price US$0.42
AnalystConsensusTarget US$3.25
AnalystHighTarget US$10.00
AnalystLowTarget US$1.50
Fair ValueUS$3.25
Share Pricen/a
Sangamo Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 32 Fair Values set on narratives written by author
SGMO Community Narratives
AN
Fair Value US$3.25 87.0% undervalued intrinsic discount
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
1users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
AN
Fair Value US$10 95.8% undervalued intrinsic discount
Aging Populations And AI Integration Will Expand Gene Therapy Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$1.5 71.8% undervalued intrinsic discount
Rising Funding Needs Will Threaten Fabry Trials And Inspire Hope
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
Key Takeaways Positive clinical data in Fabry disease and strong market enthusiasm position Sangamo for rapid adoption, margin improvement, and significant revenue growth upon approval. Progress in non-opioid neurology therapeutics, industry partnerships, and global regulatory trends expand the pipeline, derisk funding, and boost long-term revenue prospects.Read more
1users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
AN
US$3.25
87.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
78.68% p.a.
Profit Margin
7.94%
Future PE
111.07x
Share price in 2028
US$2.24
Aging Populations And AI Integration Will Expand Gene Therapy Markets
Key Takeaways Robust clinical data, rapid anticipated adoption, and regulatory support position Sangamo for strong market share and lasting margin expansion in gene therapy. Advancement in AI-driven platforms and strategic partnerships or acquisitions could significantly accelerate pipeline growth, earnings, and shareholder value.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$10
95.8% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
57.58% p.a.
Profit Margin
34.57%
Future PE
40.81x
Share price in 2028
US$6.8
Rising Funding Needs Will Threaten Fabry Trials And Inspire Hope
Key Takeaways Significant financial constraints, high operating expenses, and uncertain partnership prospects threaten commercialization and the ability to sustain late-stage and pipeline program development. Competitive pressures, regulatory changes, and pricing uncertainties may compress future margins and limit both market share and earnings growth despite strong technology and market opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1.5
71.8% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-33.25% p.a.
Profit Margin
16.25%
Future PE
171.05x
Share price in 2028
US$1.02
Recently Updated Narratives
AN
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
Fair Value: US$3.25 87.0% undervalued intrinsic discount
19 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Funding Needs Will Threaten Fabry Trials And Inspire Hope
Fair Value: US$1.5 71.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And AI Integration Will Expand Gene Therapy Markets
Fair Value: US$10 95.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sangamo Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.32
- -219.11%
- -331.28%
- 0%
About SGMO
- Founded
- 1995
- Employees
- 183
- CEO
- WebsiteView website
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
